ArticleCrohn's & colitis 3602023

Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.

Bruce E Sands et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.